Brief: Citius Oncology Signs Exclusive Commercialization Agreement With EVERSANA To Support Planned Q4 2025 Launch Of LYMPHIR
16/10/2025 13:49
Oct 16 (Reuters) - Citius Oncology Inc CTOR.O: CITIUS ONCOLOGY SIGNS EXCLUSIVE COMMERCIALIZATION AGREEMENT WITH EVERSANA TO SUPPORT PLANNED Q4 2025 LAUNCH OF LYMPHIR™ CITIUS ONCOLOGY INC: CO PLANS TO COMMERCIALLY LAUNCH LYMPHIR IN UNITED STATES IN Q4 2025 Source text: ID:nPn9H30nNa Further company coverage: CTOR.O
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules